


CNS 2010: Disorders-Therapeutics/MAP For 2010



CNS 2010:Disorders-Therapeutics combines two major information resources: **NI Research's comprehensive reviews** of all major psychiatric and neurological indications, and the therapeutics programs under development, all are fully updated and revised.

MAP:Mergers/Acquisitions/Partnering: Completely updated Big Pharma licensing performance history and deal trends. The MAP review includes rosters of the most promising licensing and M&A candidates. New for 2010 is an overview of academic center research and commercialization history.

There is nothing else like **CNS 2010: Disorders-Therapeutics**, at any price.
 439+ pages 1000 projects 350 companies

TABLE of CONTENTS: SECTION 1

MAP for 2010: Introduction
 The Status Quo: Funding
 On the Pharma Record
 CNS Licensings 2009
 Which Therapeutic Areas Attract Partnerships?
 Big Pharma vs. Biovail
 Big Pharma and the Brain: A Love-Hate Relationship
 Big/Midsize Pharma and CNS: Who is Where?
 Partnering Value Added By Clinical Development
 Partnering Leverage: Inflection Points Along the Way
 CNS Licensing Roster 2007-5/2010
 CNS Licensing Benchmarks 2007-5/2010
 Pharma Performance: Partnerships and Payments
 Milestones: Myth or Fantasy?
 Does Anyone Pay Pharma Milestones?
 Big Pharma CNS Partnering Circa 2010
 Abbott Laboratories
 Astellas
 AstraZeneca
 Biogen-Idec
 Biovail
 Boehringer Ingelheim
 Bristol Myers Squibb
 Elan
 Forest Laboratories
 GlaxoSmithKline
 Johnson and Johnson
 Lilly
 Lundbeck
 Merck
 Novartis
 Pfizer
 Roche
 Sanofi-Aventis
 2010: Where MAP Goes From Here
 Therapeutic Area Potential
 Fourteen Licensing Opportunities
 The Buyout Alternative
 Turning Ivory to Gold: Can Academia Fill the Void?
 A Non-Comprehensive Sampling of Interesting Academic Projects
 Academic Progeny and Productivity
 NIH and Neurotherapeutics Grants: Where Does the Money Go?

TABLE of CONTENTS: SECTION 2

Tables: CNS Programs by Indication
 Addiction
 Alertness/EDS
 Alzheimer's
 Amyotrophic Lateral Sclerosis (ALS)
 Anxiety
 Attention Deficit Disorder (ADHD)
 Bipolar Disorder
 Depression
 Epilepsy
 Fragile X
 Huntington's
 Insomnia
 Memory Disorders (MCI/AAMI)
 Migraine
 Multiple Sclerosis (MS)
 Neuropathic Pain
 Neuroregeneration
 Nociceptive Pain
 Parkinson's
 Schizophrenia
 Spinal Cord Injury
 Stroke
 Traumatic Brain Injury (TBI)
 Table: CNS Drug Development Programs by Company

(5 user license/1 location) _____ licenses @ **US\$6600**

NI subscribers \$5600 _____

PCNS2009 or CNS2008 purchasers \$5000 _____

Startup Companies should contact us for pricing options

Name _____

Title _____

Company _____

Telephone _____

Address _____

E-mail address _____

MC, AMEX, VISA # _____

Expires _____ **Please invoice me**